Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 54: 61-68, 2008. First published November 2, 2007; 10.1373/clinchem.2007.092825
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
clinchem.2007.092825v1
54/1/61    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (1)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sviridov, D.
Right arrow Articles by Hortin, G. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sviridov, D.
Right arrow Articles by Hortin, G. L.
Related Collections
Right arrow Proteomics and Protein Markers
(Clinical Chemistry. 2008;54:61-68.)
© 2008 American Association for Clinical Chemistry, Inc.

Proteomics and Protein Markers

Reactivity of Urinary Albumin (Microalbumin) Assays with Fragmented or Modified Albumin

Denis Sviridov1, Steven K. Drake2 and Glen L. Hortin1,a

Departments of1 Laboratory Medicine and 2 Critical Care Medicine, Warren Magnuson Clinical Center, National Institutes of Health, Bethesda, MD.

aAddress correspondence to this author at: Department of Laboratory Medicine, NIH, Building 10, Room 2C-407, Bethesda, MD 20892-1508. Fax 301-402-1885; e-mail ghortin{at}mail.cc.nih.gov.

Background: Controversy exists regarding occurrence and measurement of structural variants of albumin in urine. In this study, we examined cross-reactivity of in vitro modified albumins in assays for urine albumin (microalbumin).

Methods: We analyzed albumin modified by reagents, trypsin, or physical treatments or differing in primary sequence (animal albumins) with an immunoturbidimetric assay (Beckman LX20) using goat antiserum and a competitive immunoassay (Siemens Immulite) using a monoclonal antibody. We assessed occurrence of albumin fragments in urine by use of Western blotting of 24 specimens.

Results: Chemical modification, modest sequence substitution (gorilla albumin), or cleavage of albumin by cyanogen bromide (CNBr) had little effect on reactivity in the LX20 assay. Albumin extensively cleaved with trypsin retained partial reactivity. The Immulite assay generally was affected more severely by albumin modifications and sequence changes. Western blots of fresh urine specimens or specimens stored at –80 °C showed little albumin fragmentation, but some specimens stored for 3 years at –20 °C had extensively fragmented albumin that was detected by the LX20 but not the Immulite assay.

Conclusions: Nearly equivalent reactivity of intact albumin and CNBr fragments in the immunoturbidimetric assay indicates reactivity of antibodies with multiple epitopes throughout albumin. Therefore, it is difficult to abolish reactivity of albumin in this type of urine albumin assay. Differential sensitivity of 2 assays to albumin modification identifies a potential source of assay nonequivalence in measuring urinary albumin, particularly for specimens stored at –20 °C.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2008 by the American Association for Clinical Chemistry.